Arcturus Therapeutics (NASDAQ:ARCT) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a research report report published on Friday,Benzinga reports. The firm currently has a $63.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for Arcturus Therapeutics’ FY2028 earnings at $13.21 EPS.

Several other equities research analysts also recently weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, September 9th. Leerink Partnrs raised shares of Arcturus Therapeutics to a “strong-buy” rating in a research note on Monday, August 12th. Finally, Leerink Partners started coverage on shares of Arcturus Therapeutics in a research note on Monday, August 12th. They issued an “outperform” rating and a $70.00 price target on the stock. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Arcturus Therapeutics has an average rating of “Buy” and an average price target of $71.40.

Arcturus Therapeutics Trading Up 3.8 %

ARCT stock opened at $20.37 on Friday. Arcturus Therapeutics has a 52 week low of $17.26 and a 52 week high of $45.00. The company has a fifty day simple moving average of $20.61 and a two-hundred day simple moving average of $24.21.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.44. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.29%. The business had revenue of $41.67 million during the quarter, compared to analyst estimates of $49.16 million. During the same quarter last year, the business earned ($0.61) earnings per share. On average, equities analysts predict that Arcturus Therapeutics will post -2.6 EPS for the current fiscal year.

Insider Activity

In related news, COO Pad Chivukula sold 12,000 shares of Arcturus Therapeutics stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total value of $249,120.00. Following the completion of the sale, the chief operating officer now directly owns 435,334 shares in the company, valued at $9,037,533.84. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 15.30% of the company’s stock.

Institutional Trading of Arcturus Therapeutics

A number of institutional investors have recently bought and sold shares of ARCT. Russell Investments Group Ltd. acquired a new stake in Arcturus Therapeutics in the 1st quarter worth approximately $40,000. ProShare Advisors LLC acquired a new stake in Arcturus Therapeutics in the 1st quarter worth approximately $205,000. State Board of Administration of Florida Retirement System boosted its stake in Arcturus Therapeutics by 32.3% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 8,841 shares of the biotechnology company’s stock worth $299,000 after purchasing an additional 2,160 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its stake in Arcturus Therapeutics by 10.5% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company’s stock valued at $152,000 after acquiring an additional 428 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its stake in Arcturus Therapeutics by 5.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 17,004 shares of the biotechnology company’s stock valued at $575,000 after acquiring an additional 922 shares during the period. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.